NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Altimmune, Inc. (ALT) Stock Analysis

Altimmune, Inc. (ALT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ALT

$2.23

−$0.07 (−3.04%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ALT with… →

ALT Key Statistics

As of Oct 21, 2026
Trading
Open
$2.31
Previous Close
$2.30
Day's Range
2.19–2.35
52-Week Range
2.17–6.44
Volume
4.49M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.06
Valuation
Market Cap
$433.77M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
32.62
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.76
Financials (FY)
Revenue (FY)
$41.00K+105.00%
Net Income (FY)
−$88.09M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
194.52M
1-Year Return
−44.80%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
4.28M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ALT closed at $2.23, −44.80% over 1 year.

Altimmune, Inc. (ALT) has a market capitalization of $433.77M.

In fiscal 2025, ALT reported revenue of $41.00K.

ALT Stock Return by Calendar Year

Altimmune, Inc. (ALT) return since May 2017: what $10,000 became

1 year
$10,000 $5,520
−44.80%
5 years
$10,000 $1,890
−81.10%
Since May 2017
$10,000 $167
−98.33%

If you had invested $10,000 in Altimmune, Inc. (ALT) at the close on May 26, 2017, the earliest close on record here, it would have been worth $167 at the close on October 21, 2026: −98.33% in total, −35.27% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−38.23%
2025−49.93%
2024−35.91%
2023−31.61%
2022+79.59%
2021−18.79%
2020+496.83%
2019−8.25%
2018−96.55%
2017 (partial year)−55.18%

As of October 21, 2026.

ALT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$41.00K−$88.09M−214,861.0%
2024$20.00K−$95.06M−475,295.0%
2023$426.00K−$88.45M−20,762.2%
2022−$68.00K−$84.71M124,577.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$41.00K—−$94.49M−$88.09M−214,861.0%
2024$20.00K—−$103.17M−$95.06M−475,295.0%
2023$426.00K—−$83.51M−$88.45M−20,762.2%
2022−$68.00K—−$87.74M−$84.71M124,577.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Altimmune, Inc. (ALT) carries a market capitalisation of $433.77M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 57 employees.

ALT last closed at $2.23 on October 21, 2026. That is −$0.07 (−3.04%) against the previous close. The 52-week range on file runs from $2.17 to $6.44. The latest close sits 2.76% above that 52-week low.

Financial Health

In fiscal 2025, Altimmune, Inc. reported revenue of $41.00K. Against the prior fiscal year total of $20.00K, that is a change of +105.00%. The same year closed with a net loss of $88.09M. Earnings per share on a trailing basis come to −0.76.

Across the 4 fiscal years on file, revenue moves from −$68.00K in 2022 to $41.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The PEG ratio, which sets the P/E against expected earnings growth, reads 32.62.

Beta against the wider market is reported at 0.06. Daily returns over the trailing 9 years annualize to a volatility of 146.01%. The trailing one-year total return is −44.80%. Measured over 5 years, that is −28.34% a year compounded.

Growth & Income

The record shows no dividend for ALT.

So far in 2026 the total return is −38.23%. Across the complete calendar years on file, 2020 returned +496.83% and 2018 returned −96.55%. Of the 8 complete calendar years on file, 2 finished higher.

Peer Comparison

Altimmune, Inc. (ALT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Altimmune, Inc. ALT $433.77M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Altimmune, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Altimmune, Inc.

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Visit website →